LifeSpan: Genomics for a new 'age'

The lasting benefit of genomic approaches to drug discovery may be to force biotechnology and pharmaceutical companies to reevaluate how disease targets are chosen. With an abundance of sequence information, the question is not how to isolate genes of interest but which model system should be used to study gene expression. LifeSpan BioSciences, a genomics company focused on the chronic diseases associated with aging, believes that the way to validate gene targets is

Read the full 739 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers